MYUNGIN PHARM.CO., LTD
Founded in 1988 and KOSPI-listed in 2025, Myungin Pharm makes CNS prescription drugs and OTC brands Yigatan F and Makin Q.
As of 2026-10-11, MYUNGIN PHARM.CO., LTD has 371 Korean MFDS drug approvals on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureMyungin Pharm was founded in 1988 and listed on the KOSPI in October 2025, specializing in central nervous system (CNS) prescription drugs. It manufactures and sells prescription treatments for stroke, Parkinson's disease, schizophrenia, and depression, alongside OTC products such as the gum-disease treatment Yigatan F and the constipation remedy Makin Q. The company runs a full production chain from active pharmaceutical ingredient synthesis to finished dosage forms, held the No. 1 share of Korea's CNS drug market per IQVIA's 2025 Q4 data, and has formed partnerships with global pharmaceutical companies to expand into the US, European, Chinese, and Japanese markets.
Products & technology
- Yigatan FOver-the-counter gum disease treatment
- Makin QOver-the-counter constipation remedy
Regulatory approvals
data.go.kr371 Korean MFDS drug approvals · 1985–2026
- MFDS drugRepizole Tab. 20mg2026-01-23Drug · Prescription · Approval202600202
- MFDS drugBuripam Tab. 10mg2025-10-28Drug · Prescription · Approval202502766
- MFDS drugBuripam Tab. 25mg2025-10-28Drug · Prescription · Approval202502767
- MFDS drugBuripam Tab. 50mg2025-10-28Drug · Prescription · Approval202502768
- MFDS drugBuripam Tab. 100mg2025-10-28Drug · Prescription · Approval202502769
- MFDS drugSpeeda Tab.2025-08-25Drug · OTC · Notification202502194
- MFDS drugMotin Inj.2025-08-20Drug · Prescription · Approval202502157
- MFDS drugRiselton Multi-Day Patch 51.84mg(Rivastigmine)2025-08-19Drug · Prescription · Approval202502150
- MFDS drugRiselton Multi-Day Patch 25.92mg(Rivastigmine)2025-08-19Drug · Prescription · Approval202502151
- MFDS drugMayqueen F EC Tab.2025-07-17Drug · OTC · Notification202501823
- MFDS drugFrotriptan tab. 2.5mg2025-06-26Drug · Prescription · Approval202501584
- MFDS drugS-Ven ER Tab. 25mg2025-04-21Drug · Prescription · Approval202500935
Show 68 more
- MFDS drugAmonil Tab. 250mg2025-03-31Drug · Prescription · Approval202500739
- MFDS drugAmonil Tab. 150mg2025-03-31Drug · Prescription · Approval202500740
- MFDS drugSilvercept Tab. 3mg2025-02-27Drug · Prescription · Approval202500434
- MFDS drugFello Tab. 20mg2024-07-29Drug · Prescription · Approval202401820
- MFDS drugMyungdopar Tab. 12.5/50mg2023-05-17Drug · Prescription · Approval202301581
- MFDS drugNEWPRAM OD Tab. 20mg2023-05-16Drug · Prescription · Approval202301560
- MFDS drugNEWPRAM OD Tab. 10mg2023-05-16Drug · Prescription · Approval202301561
- MFDS drugNEWPRAM OD Tab. 5mg2023-05-16Drug · Prescription · Approval202301562
- MFDS drugFello OD Tab. 20mg2023-05-01Drug · Prescription · Approval202301421
- MFDS drugVoxetine Tab. 5mg2023-04-17Drug · Prescription · Approval202301253
- MFDS drugVoxetine Tab. 10mg2023-04-17Drug · Prescription · Approval202301254
- MFDS drugVoxetine Tab. 15mg2023-04-17Drug · Prescription · Approval202301255
- MFDS drugVoxetine Tab. 20mg2023-04-17Drug · Prescription · Approval202301256
- MFDS drugTraline Tab. 25mg2022-11-22Drug · Prescription · Approval202204212
- MFDS drugHealth Vita Tab.2022-11-04Drug · OTC · Notification202203993
- MFDS drugRepizole Tab. 2mg2022-08-29Drug · Prescription · Approval202203419
- MFDS drugRepizole Tab. 1mg2022-08-29Drug · Prescription · Approval202203420
- MFDS drugMyungintolvaptan Tab. 30mg2022-06-23Drug · Prescription · Approval202202617
- MFDS drugMirta Tab. 45mg2022-05-11Drug · Prescription · Approval202201970
- MFDS drugRiselton patch 152022-05-11Drug · Prescription · Approval202202061
- MFDS drugParox Tab. 10mg2022-04-25Drug · Prescription · Approval202201670
- MFDS drugPericompa Tab. 2mg2022-04-05Drug · Prescription · Approval202201450
- MFDS drugPericompa Tab. 12mg2022-04-05Drug · Prescription · Approval202201451
- MFDS drugPericompa Tab. 10mg2022-04-05Drug · Prescription · Approval202201452
- MFDS drugPericompa Tab. 8mg2022-04-05Drug · Prescription · Approval202201453
- MFDS drugPericompa Tab. 6mg2022-04-05Drug · Prescription · Approval202201454
- MFDS drugPericompa Tab. 4mg2022-04-05Drug · Prescription · Approval202201455
- MFDS drugPD-PEXOL ER Tab. 1.5mg2021-12-31Drug · Prescription · Approval202108205
- MFDS drugPD-PEXOL ER Tab. 0.75mg2021-12-31Drug · Prescription · Approval202108206
- MFDS drugPD-PEXOL Tab. 0.25mg2021-11-30Drug · Prescription · Approval202107701
- MFDS drugPD-PEXOL Tab. 0.125mg2021-11-30Drug · Prescription · Approval202107702
- MFDS drugPD-PEXOL Tab. 0.5mg2021-11-30Drug · Prescription · Approval202107703
- MFDS drugPD-PEXOL Tab. 1mg2021-11-30Drug · Prescription · Approval202107704
- MFDS drugBiolamin Gold Tab.2021-10-26Drug · OTC · Notification202107128
- MFDS drugPD-PEXOL ER Tab. 0.375mg2021-09-23Drug · Prescription · Approval202106621
- MFDS drugMyungdopar Tab. 25/100mg2021-06-03Drug · Prescription · Approval202104353
- MFDS drugMyungdopar Tab. 50/200mg2021-05-14Drug · Prescription · Approval202103852
- MFDS drugFello OD Tab. 10mg2020-10-30Drug · Prescription · Approval202007459
- MFDS drugFello OD Tab. 5mg2020-10-30Drug · Prescription · Approval202007460
- MFDS drugMyungin Rivaroxaban Tab. 10mg2020-07-23Drug · Prescription · Approval202005291
- MFDS drugMyungin Rivaroxaban Tab. 15mg2020-07-23Drug · Prescription · Approval202005292
- MFDS drugMyungin Tolvaptan Tab. 15mg2020-06-30Drug · Prescription · Approval202004774
- MFDS drugFello Tab. 5mg2020-05-21Drug · Prescription · Approval202003712
- MFDS drugMyungin Rivaroxaban Tab. 2.5mg2020-04-10Drug · Prescription · Approval202002559
- MFDS drugS-Ven ER Tab. 50mg2020-04-07Drug · Prescription · Approval202002457
- MFDS drugS-Ven ER Tab. 100mg2020-04-07Drug · Prescription · Approval202002458
- MFDS drugZoss Tab. 1mg2020-03-30Drug · Prescription · Approval202002178
- MFDS drugZoss Tab. 3mg2020-03-30Drug · Prescription · Approval202002179
- MFDS drugZoss Tab. 2mg2020-03-30Drug · Prescription · Approval202002180
- MFDS drugMyungin Rivaroxaban Tab. 20mg2020-03-18Drug · Prescription · Approval202001884
- MFDS drugPerkin CR Tab. 50-200mg2019-10-31Drug · Prescription · Approval201907607
- MFDS drugRasalin Tab. 1mg2019-10-22Drug · Prescription · Approval201907384
- MFDS drugRasalin Tab. 0.5mg2019-10-22Drug · Prescription · Approval201907385
- MFDS drugClopic Tab.2019-04-30Drug · Prescription · Approval201902793
- MFDS drugMyungin Hydrocortisone Inj. 100mg2019-03-27Drug · Prescription · Approval201901824
- MFDS drugMyungin Hydrocortisone Inj. 300mg2019-03-27Drug · Prescription · Approval201901825
- MFDS drugMyungin Hydrocortisone Inj. 1000mg2019-03-27Drug · Prescription · Approval201901826
- MFDS drugMyungin Hydrocortisone Inj. 500mg2019-03-27Drug · Prescription · Approval201901827
- MFDS drugPakinol PD Tab. 2mg2019-03-07Drug · Prescription · Approval201901412
- MFDS drugPakinol PD Tab. 8mg2019-03-07Drug · Prescription · Approval201901418
- MFDS drugPakinol PD Tab. 4mg2019-03-07Drug · Prescription · Approval201901419
- MFDS drugKonil Tab. 2mg2019-02-22Drug · Prescription · Approval201901134
- MFDS drugMyungin Acamprosate Tab. 333mg2019-01-25Drug · Prescription · Notification201900645
- MFDS drugQ-Rokel Tab. 12.5mg2019-01-17Drug · Prescription · Approval201900219
- MFDS drugQ-Pam XR Tab. 750mg2018-12-20Drug · Prescription · Approval201805180
- MFDS drugQ-Pam XR Tab. 500mg2018-12-20Drug · Prescription · Approval201805181
- MFDS drugPregal Cap. 50mg2018-11-19Drug · Prescription · Approval201804578
- MFDS drugPregal Cap. 25mg2018-11-19Drug · Prescription · Approval201804579
Showing the 80 most recent of 371 records.
Clinical trials
data.go.kr60 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 58 · Phase 3 1 · Phase 1 1)
- BioequivalenceMI25042026-05-20
2 trial sites
- Bioequivalence지프라캡슐20밀리그램2026-02-04
2 trial sites
- BioequivalenceMI25032025-10-24
2 trial sites
- Phase 3NW-35092025-08-01
5 trial sites
- BioequivalenceMI25022025-07-17
2 trial sites
- BioequivalenceMI25012025-05-15
2 trial sites
- Phase 1팍스로야캡슐2025-02-28
2 trial sites
- Bioequivalence그로민캡슐25밀리그램(클로미프라민염산염)2024-12-13
2 trial sites
- Bioequivalence푸로트란정2.5밀리그램2024-03-26
2 trial sites
- Bioequivalence명세핀정6밀리그램(독세핀염산염)2023-07-10
2 trial sites
- Bioequivalence헬스피온엑스엘정300밀리그램(부프로피온염산염)2023-05-24
2 trial sites
- Bioequivalence아모닐정250밀리그램(아모다피닐)2023-03-20
2 trial sites
Show 48 more
- Bioequivalence명세핀정6밀리그램(독세핀염산염)2023-03-08
2 trial sites
- Bioequivalence조스정1밀리그램(에스조피클론)2022-08-22
2 trial sites
- Bioequivalence드록틴캡슐60밀리그램(둘록세틴염산염)2022-06-09
2 trial sites
- Bioequivalence보세틴정10밀리그램(보티옥세틴브롬화수소산염)2022-01-25
2 trial sites
- Bioequivalence클로픽정(클로피도그렐황산수소염)2021-10-29
2 trial sites
- Bioequivalence뉴프람오디정20밀리그램(에스시탈로프람옥살산염)2021-08-12
2 trial sites
- Bioequivalence레피졸정2밀리그램(아리피프라졸)2021-08-02
2 trial sites
- Bioequivalence파록스정20밀리그램(파록세틴염산염수화물)2020-11-06
2 trial sites
- Bioequivalence페리콤파정12밀리그램(페람파넬)2020-07-23
2 trial sites
- Bioequivalence올스타틴정20mg(로수바스타틴칼슘)2020-03-17
2 trial sites
- Bioequivalence피디펙솔서방정0.375밀리그램2020-02-11
2 trial sites
- Bioequivalence피디펙솔서방정0.375밀리그램2020-02-04
2 trial sites
- Bioequivalence라사린오디정1밀리그램(라사길린메실산염)2019-09-18
2 trial sites
- Bioequivalence명인갈란타민서방캡슐8밀리그램(갈란타민브롬화수소산염)2019-08-13
2 trial sites
- Bioequivalence명인갈란타민서방캡슐8밀리그램(갈란타민브롬화수소산염)2019-08-13
2 trial sites
- Bioequivalence펠로오디정10밀리그램(메만틴염산염)2019-07-04
2 trial sites
- Bioequivalence명도파정2019-05-21
2 trial sites
- Bioequivalence명인톨밥탄정15밀리그램(가칭)2019-05-17
2 trial sites
- Bioequivalence라사린정(라사길린메실산염)2018-05-14
2 trial sites
- Bioequivalence퍼킨씨알정50/200mg2018-03-29
2 trial sites
- Bioequivalence큐팜엑스알서방정500밀리그램(레비티라세탐)2018-03-09
2 trial sites
- Bioequivalence코팩사엑스알서방캡슐75mg(벤라팍신염산염)2017-08-24
2 trial sites
- Bioequivalence명인트라조돈캅셀25밀리그람2017-01-24
1 trial site
- Bioequivalence명인아캄프로세이트정(Acamprosate calcium 333mg)2017-01-19
2 trial sites
- Bioequivalence명인아미트리프틸린염산염정10밀리그람2017-01-18
2 trial sites
- Bioequivalence명인이미프라민염산염정2016-11-11
2 trial sites
- Bioequivalence명인페니토인100밀리그람정2016-10-28
1 trial site
- Bioequivalence명인벤즈트로핀메실레이트정2밀리그람2016-10-19
2 trial sites
- Bioequivalence실버셉트오디정10밀리그램(도네페질염산염수화물)2016-07-11
- Bioequivalence리스펜오디정1밀리그램(리스페리돈)2016-07-11
- Bioequivalence명인디아제팜정5밀리그람2016-06-22
2 trial sites
- Bioequivalence트리레보정 200 / 50 / 200 밀리그램2016-05-31
1 trial site
- Bioequivalence팔리펜서방정6밀리그램2016-03-18
2 trial sites
- Bioequivalence슈퍼피린캡슐(변경 후)2015-10-14
2 trial sites
- Bioequivalence명인갈란타민서방캡슐8밀리그램(갈란타민브롬화수소산염)2015-09-24
2 trial sites
- Bioequivalence실버셉트정23mg(도네페질염산염)2015-05-22
2 trial sites
- Bioequivalence트리레보정75/18.75/200mg2015-02-27
2 trial sites
- Bioequivalence루나팜정(플루니트라제팜)2015-01-23
- Bioequivalence트리레보정125/31.25/200mg2014-07-25
2 trial sites
- Bioequivalence올메디핀정5/20mg2014-07-11
2 trial sites
- Bioequivalence뉴로자핀정10밀리그램(올란자핀)2014-06-05
- Bioequivalence큐로켈서방정200mg(쿠에티아핀푸마르산염)2014-05-28
2 trial sites
- Bioequivalence명인트라조돈염산염정50mg2013-07-19
- Bioequivalence리스펜오디정1밀리그램(리스페리돈)2013-01-23
- Bioequivalence에스살탄플러스정10/160밀리그램2013-01-14
1 trial site
- Bioequivalence아이살탄정300mg(이르베사르탄)2013-01-04
1 trial site
- Bioequivalence슈퍼피린캡슐2012-12-31
2 trial sites
- Bioequivalence드록틴캡슐60밀리그램(둘록세틴염산염)2012-07-26
2 trial sites
R&D and key agreements
Source: DART corporate disclosureP2B001(팍스로야, PAXROYA) · 파킨슨병 · 품목허가심사단계 · Licensed from Pharma Two B (Israel); Korean marketing authorization application filed Sep 2025; Myungin acquired related IP after Pharma Two B's Jan 2026 liquidation
NW-3509(에베나마이드, Evenamide) · 치료저항성 조현병 보조치료 · 임상3상 · Licensed from Newron Pharmaceuticals (Italy); US FDA Phase 3 approval May 2025, Korean MFDS Phase 3 approval Aug 2025
Patents
KIPRIS · applicant-matchedRegistered · 2020-02 · Application 1020200019959
Rejected · 2019-12 · Application 1020190166942
Expired · 1996-07 · Application 1019960029900
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot75
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 26, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for MYUNGIN PHARM.CO., LTD and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition